Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Current Assets (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Current Assets readings, the most recent being $17.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 48.8% year-over-year to $17.7 million, compared with a TTM value of $17.7 million through Dec 2025, down 48.8%, and an annual FY2025 reading of $17.7 million, down 48.8% over the prior year.
  • Current Assets hit $17.7 million in Q4 2025 for Lisata Therapeutics, down from $21.6 million in the prior quarter.
  • The five-year high for Current Assets was $65.3 million in Q1 2023, with the low at $17.7 million in Q4 2025.
  • Median Current Assets over the past 3 years was $39.8 million (2024), compared with a mean of $41.0 million.
  • The sharpest move saw Current Assets dropped 27.17% in 2024, then crashed 48.8% in 2025.
  • Year by year, Current Assets stood at $53.9 million in 2023, then plummeted by 35.88% to $34.6 million in 2024, then tumbled by 48.8% to $17.7 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $17.7 million, $21.6 million, and $24.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.